1. Academic Validation
  2. Matairesinol ameliorates experimental autoimmune uveitis by suppression of IRBP-specific Th17 cells

Matairesinol ameliorates experimental autoimmune uveitis by suppression of IRBP-specific Th17 cells

  • J Neuroimmunol. 2020 Aug 15;345:577286. doi: 10.1016/j.jneuroim.2020.577286.
Xin Li 1 Qiang Gao 1 Lei Yang 1 Meng Han 1 Chunlei Zhou 1 Hong Mu 2
Affiliations

Affiliations

  • 1 Department of Clinical Laboratory, Tianjin First Centre Hospital, Tianjin, China.
  • 2 Department of Clinical Laboratory, Tianjin First Centre Hospital, Tianjin, China. Electronic address: [email protected].
Abstract

We investigated the effects of matairesinol (MAT) in the experimental autoimmune uveitis (EAU), a classical animal model of uveitis. We found that treatment with MAT could alleviate intraocular inflammation of EAU. Notably, Th17 cells in eyes of EAU mice could be predominantly restrained by MAT. Furthermore, MAT could inhibit Th17 differentiation in vitro. In addition, MAT inhibited the signaling of MAPK and ROR-γt, a pivotal transcription factor for Th17 cell differentiation in vitro and in vivo. Taken together, these results suggested that MAT had immune-suppressive effects on autoimmune inflammation through Th17 cells.

Keywords

EAU; MAPK; Matairesinol; ROR-γt; Th17 cells.

Figures
Products